within Pharmacolibrary.Drugs.ATC.P;

model P02CA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 3.8333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 900
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P02CA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Flubendazole is a benzimidazole anthelmintic drug primarily used to treat gastrointestinal and tissue infections caused by nematode worms. It has been used in both human and veterinary medicine, but it is not widely approved for use in humans in many countries. Its primary mechanism is inhibition of tubulin polymerization, impairing glucose uptake and depleting energy stores in susceptible parasites.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult humans after oral administration, as no formal population PK studies are available. Published data indicate very poor oral bioavailability due to low solubility and extensive first-pass metabolism.</p><h4>References</h4><ol><li><p>Michiels, M, et al., &amp; van den Bossche, H (1982). The pharmacokinetics of mebendazole and flubendazole in animals and man. <i>Archives internationales de pharmacodynamie et de therapie</i> 256(2) 180–191. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7103610/\">https://pubmed.ncbi.nlm.nih.gov/7103610</a></p></li><li><p>Vigh, T, et al., &amp; Nagy, ZK (2017). Oral bioavailability enhancement of flubendazole by developing nanofibrous solid dosage forms. <i>Drug development and industrial pharmacy</i> 43(7) 1126–1133. DOI:<a href=\"https://doi.org/10.1080/03639045.2017.1298121\">10.1080/03639045.2017.1298121</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28274133/\">https://pubmed.ncbi.nlm.nih.gov/28274133</a></p></li><li><p>Lachau-Durand, S, et al., &amp; Lampo, A (2019). Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients. <i>PLoS neglected tropical diseases</i> 13(1) e0007026–None. DOI:<a href=\"https://doi.org/10.1371/journal.pntd.0007026\">10.1371/journal.pntd.0007026</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30650076/\">https://pubmed.ncbi.nlm.nih.gov/30650076</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P02CA05;
